Current Hematologic Malignancy Reports

, Volume 8, Issue 4, pp 317–324

Preclinical Models for Drug Selection in Myeloproliferative Neoplasms

  • Niccolò Bartalucci
  • Costanza Bogani
  • Alessandro M. Vannucchi
Myeloproliferative Disorders (JJ Kiladjian, Section Editor)

DOI: 10.1007/s11899-013-0182-1

Cite this article as:
Bartalucci, N., Bogani, C. & Vannucchi, A.M. Curr Hematol Malig Rep (2013) 8: 317. doi:10.1007/s11899-013-0182-1
  • 166 Downloads

Abstract

The discovery that an abnormally activated JAK-STAT signaling pathway is central to the pathogenesis of myeloproliferative neoplasms has promoted the clinical development of small-molecule JAK2 inhibitors. These agents have shown remarkable efficacy in disease control, but do not induce molecular remission; on the other hand, interferon holds the promise to target the putative hematopoietic progenitor cell initiating the disease. The presence of additional molecular abnormalities indicates a high molecular complexity of myeloproliferative neoplasms, and the need for simultaneously targeting different targets. Several drugs are currently under study as single agents and in combination. This review briefly describes the several in vitro and in vivo models of myeloproliferative neoplasms that are being used as preclinical models for drug development.

Keywords

Myeloproliferative neoplasmsJAK2 mutationAnimal modelsJAK2 inhibitorsMyelofibrosisHematologic malignancy

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Niccolò Bartalucci
    • 1
  • Costanza Bogani
    • 1
  • Alessandro M. Vannucchi
    • 1
    • 2
  1. 1.Department of Experimental and Clinical MedicineUniversity of FlorenceFlorenceItaly
  2. 2.Department of Medical and Surgical CareUniversity of FlorenceFlorenceItaly